PART TWO: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part Two of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) summaries the rationale, design and eligibility criteria of his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia, and summarizes the key take-home conclusions. A total of 55 patients were treated and the combination therapy showed complete molecular response. These data could present a potential paradigm shift in treatment options for Philadelphia chromosome-positive ALL.
Abstract: S114: ‘PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY’ was presented at the EHA annual meeting 2022.
- What were the aims, design and eligibility criteria of the Phase II study? (00:16-02:11)
- What have we learned from the latest efficacy and safety findings of the study? (02:11-04:12)
Disclosures: Nicholas Short is consultant for Pfizer Inc., Jazz Pharmaceuticals and Sanofi. He has received grant/research support from Takeda Oncology, Astellas Pharma Inc., Xencor and Stemline Therapeutics, and honoraria/honorarium from Novartis, Amgen and Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 27th Congress of the European Hematology Association (EHA).
Share this Video
Related Videos In Leukaemia
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia – results from a phase II pivotal clinical trial
Professor Jorge Cortes (Georgia Cancer Center, GA, USA) discusses the results from a recent clinical trial that were presented at ASH 2022. Abstract 2757: ‘Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial‘ Disclosures: Jorge Cortes is a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!